title: [Bone diseases].
abstract: Calcium intake shows a small impact on bone mineral density and fracture risk. Denosumab is a more potent inhibitor of bone resorption than zoledronate. Abaloparatide, PTHrP analog, increases bone mineral density and decreases fracture incidence. Teriparatide could be delivered via a transdermic device. Romosozumab and odanacatib improve calculated bone strength. Sequential or combined treatments with denosumab and teriparatide could be of interest, but not denosumab followed by teriparatide. Fibrous dysplasia, Paget disease and hypophosphatasia are updated, as well as atypical femoral fracture and osteonecrosis of the jaw.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Uebelhart
authors.forename: René
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001847:Bone Diseases / Q000188:drug therapy* / Q000503:physiopathology; D002118:Calcium / Q000008:administration & dosage; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans
chemical_list: D050071:Bone Density Conservation Agents; D002118:Calcium